--- title: "Ozempic Lawsuit: Gastroparesis and GLP-1 Receptor Agonist Claims" url: https://www.masstortmarketingagency.com/blogs/ozempic-lawsuit-gastroparesis canonical: https://www.masstortmarketingagency.com/blogs/ozempic-lawsuit-gastroparesis published: 2026-02-20 modified: 2026-02-20 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | Litigation resource on Ozempic and GLP-1 receptor agonist claims: gastroparesis, bowel obstruction, pancreatitis, and gallbladder injuries; FDA adverse event data and the September 2023 ileus label update; MDL No. 3094 (E.D. Pa.) against Novo Nordisk and Eli Lilly; settlement projections from $50K moderate cases to $1M+ severe cases. keywords: - Ozempic lawsuit - gastroparesis - GLP-1 receptor agonist litigation - MDL 3094 - Novo Nordisk - Eli Lilly license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Ozempic lawsuit: gastroparesis and GLP-1 receptor agonist claims > **Quick answer.** Ozempic/GLP-1 product liability cases are > consolidated in MDL No. 3094 (created August 2023, Eastern District of > Pennsylvania) against Novo Nordisk and Eli Lilly. Qualifying injuries > include gastroparesis, bowel obstruction/ileus, pancreatitis, > gallbladder disease requiring surgery, and aspiration during > anesthesia. More than 40 million GLP-1 prescriptions were dispensed > annually in the U.S. by 2024; Novo Nordisk's semaglutide revenue > exceeded $21 billion in 2023. Severe gastroparesis cases are projected > at $200,000–$1 million+; moderate documented GI injuries at > $50,000–$200,000. ## Why GLP-1 litigation is a defining mass tort The rapid rise of GLP-1 receptor agonist medications — including semaglutide (Ozempic and Wegovy) and liraglutide (Saxenda and Victoza) — has been accompanied by growing reports of severe gastrointestinal injuries that manufacturers allegedly failed to adequately warn about. Gastroparesis, bowel obstruction, pancreatitis, and gallbladder disease have been reported by thousands of patients, producing an emerging wave of product liability litigation against Novo Nordisk and Eli Lilly. By 2024, more than **40 million GLP-1 prescriptions** were dispensed annually in the United States. Novo Nordisk's revenue from semaglutide products exceeded **$21 billion in 2023**. The combination of massive prescription volumes, a well-understood injury mechanism, growing adverse event data, and allegations of inadequate warnings creates a compelling litigation framework. ## Understanding GLP-1 receptor agonist medications GLP-1 receptor agonists mimic glucagon-like peptide-1: they stimulate insulin secretion, reduce glucagon production, slow gastric emptying, and promote satiety. The delayed gastric emptying effect — useful for appetite suppression — is the mechanism that causes gastroparesis and other GI injuries. ### Semaglutide products Ozempic (FDA-approved December 2017 for type 2 diabetes) is widely prescribed off-label for weight loss. Wegovy (approved June 2021 for chronic weight management) uses higher doses up to 2.4 mg, which may increase GI adverse event risk. Rybelsus (approved September 2019) is the oral tablet form. ### Tirzepatide products Tirzepatide, manufactured by Eli Lilly, is a dual GIP/GLP-1 receptor agonist sold as Mounjaro (approved May 2022 for diabetes) and Zepbound (approved November 2023 for weight management). Its GI side effect profile is similar to semaglutide, making Eli Lilly a co-defendant. ## How GLP-1 agonists cause gastrointestinal injuries The injury mechanism is directly related to the drugs' therapeutic action. GLP-1 agonists slow gastric emptying by design, but in some patients the effect becomes pathological — the stomach cannot empty adequately, resulting in gastroparesis that can become chronic and persist after discontinuation. - **Intestinal dysmotility and bowel obstruction:** GLP-1 receptors throughout the GI tract reduce intestinal motility, potentially causing bowel obstruction, ileus, and severe constipation requiring surgical intervention. The American Society of Anesthesiologists issued 2023 guidance warning of aspiration risk during anesthesia in GLP-1 patients. - **Pancreatic and gallbladder effects:** Chronic overstimulation of pancreatic cells may trigger pancreatitis and potentially increase pancreatic cancer risk. GLP-1 agonists are associated with gallstones, cholecystitis, and choledocholithiasis due to reduced gallbladder motility and altered bile composition. ## Gastroparesis: the central injury in Ozempic litigation Gastroparesis — stomach paralysis — is the primary injury driving GLP-1 litigation. Patients experience persistent nausea, vomiting of undigested food, severe abdominal pain, early satiety, weight loss, malnutrition, and erratic blood glucose levels. A critical allegation is that GLP-1-induced gastroparesis can become chronic, persisting long after the medication is stopped. While Novo Nordisk's prescribing information acknowledges delayed gastric emptying, plaintiffs allege the labels did not adequately warn that this effect could become permanent. ## Qualifying injuries and claim types - **Gastroparesis:** Diagnosed via gastric emptying study. Cases requiring hospitalization, gastric stimulator implantation, or extended treatment are strongest. - **Bowel obstruction / ileus:** Documented by imaging. Surgical intervention (exploratory laparotomy, bowel resection, colostomy) strengthens the case. - **Pancreatitis:** Acute or chronic, confirmed by elevated lipase/amylase and imaging. Severe necrotizing pancreatitis has mortality rates above 20%. - **Gallbladder disease:** Gallstones, cholecystitis, and cholecystectomy during or after GLP-1 use. Rapid weight loss increases gallstone formation risk. - **Aspiration during anesthesia:** Aspiration events during surgery due to residual gastric contents despite normal fasting. - **Thyroid cancer concerns:** Black box warning about thyroid C-cell tumors from animal studies; some patients developed medullary thyroid carcinoma after GLP-1 use. ## FDA adverse event reports and regulatory actions The FDA Adverse Event Reporting System (FAERS) has received tens of thousands of reports related to semaglutide products. In **September 2023**, the FDA updated Ozempic's prescribing information to add "ileus" as a reported adverse reaction — an acknowledgment plaintiffs argue came too late. Ongoing FDA safety reviews examine aspiration during anesthesia, suicidal ideation reports, and pancreatitis and thyroid cancer signals. ## The failure-to-warn legal theory The primary theory is that manufacturers did not adequately warn about gastroparesis as a persistent and potentially permanent condition, the severity of GI symptoms, the risk of bowel obstruction and ileus (until the 2023 label update), and the possibility that effects persist after discontinuation. ### The learned intermediary exception Extensive direct-to-consumer advertising for Ozempic and Wegovy may create an exception to the learned intermediary doctrine: DTC marketing minimized side effects while emphasizing weight loss benefits, potentially circumventing the defense. Some plaintiffs also pursue design defect claims, arguing GLP-1 agonists are unreasonably dangerous for weight loss patients. ## MDL 3094 and current litigation status In August 2023, the JPML created **MDL No. 3094, In re: Ozempic (Semaglutide) and Mounjaro (Tirzepatide) Products Liability Litigation**, consolidating federal GLP-1 cases in the Eastern District of Pennsylvania. The MDL includes thousands of pending cases with new filings continuing rapidly. Early discovery focuses on internal documents regarding knowledge of GI risks, clinical trial data on gastroparesis rates, and warning label adequacy. ## Defendants: Novo Nordisk and Eli Lilly | Defendant | Products | Market cap | Mechanism | |---|---|---|---| | Novo Nordisk | Ozempic, Wegovy, Rybelsus, Victoza, Saxenda | $500B+ | GLP-1 agonist | | Eli Lilly | Mounjaro, Zepbound | $700B+ | Dual GIP/GLP-1 | Both defendants have enormous financial resources and have retained top defense firms. Their primary strategy argues that GLP-1 labels adequately warned about GI side effects and that individual conditions were caused by other factors. ## Settlement projections and case valuation | Injury severity | Projected range | Key factors | |---|---|---| | Severe gastroparesis | $200K – $1M+ | Surgery, hospitalization, ongoing treatment | | Bowel obstruction / surgery | $200K – $1M+ | Surgical intervention, permanent changes | | Pancreatitis | $100K – $500K+ | Chronic cases highest value | | Moderate GI injury | $50K – $200K | Documented but less severe | These projections may change as the litigation develops. ## Building a strong Ozempic case Effective case building requires pharmacy fill records documenting the specific GLP-1 medication, dosage, and dates of use; medical records documenting the injury (gastric emptying study results, imaging for bowel obstruction, lab results for pancreatitis, surgical records); and pre-GLP-1 medical records demonstrating normal GI function before the medication. ### Medical causation strategy General causation is strongly supported by known pharmacology — delayed gastric emptying is a designed effect. Gastroenterologists provide specific causation via differential diagnosis; pharmacologists explain the dose-response relationship. The FDA's inclusion of ileus in the Ozempic label and the volume of FAERS reports support both general and specific causation. ## How to acquire Ozempic claimants SEM campaigns targeting "Ozempic lawsuit," "Ozempic gastroparesis lawyer," and "GLP-1 stomach paralysis" reach individuals actively seeking counsel. Pre-qualified Ozempic leads from Mass Tort Agency (https://www.masstortmarketingagency.com/mass-tort-leads/ozempic) offer a direct pipeline, supplemented by patient community outreach, healthcare provider referrals from gastroenterologists and endocrinologists, and content marketing about GLP-1 side effects. ## Frequently asked questions ### What is gastroparesis and how does Ozempic cause it? Gastroparesis is a condition where the stomach cannot empty its contents normally, causing nausea, vomiting, bloating, and abdominal pain. Ozempic and other GLP-1 receptor agonists work in part by slowing gastric emptying; in some patients this effect becomes excessive and persistent, leading to clinical gastroparesis that may continue even after the medication is stopped. ### What injuries qualify for an Ozempic lawsuit? Gastroparesis (stomach paralysis), bowel obstruction or ileus, pancreatitis (acute or chronic), gallbladder disease requiring surgery, and aspiration injuries during anesthesia. The injury must have occurred during or shortly after GLP-1 use with no prior history of the condition. ### Which medications are included in GLP-1 litigation? Ozempic, Wegovy, and Rybelsus (semaglutide, Novo Nordisk); Mounjaro and Zepbound (tirzepatide, Eli Lilly); and Victoza and Saxenda (liraglutide, Novo Nordisk). Other GLP-1 receptor agonists may also be included. ### Who are the defendants in Ozempic lawsuits? Novo Nordisk (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda) and Eli Lilly (Mounjaro, Zepbound). ### Is there an MDL for Ozempic cases? Yes. MDL No. 3094 was created in August 2023 in the Eastern District of Pennsylvania, consolidating federal GLP-1 receptor agonist product liability cases against Novo Nordisk and Eli Lilly. ### How much is an Ozempic lawsuit worth? Severe gastroparesis cases requiring surgery or ongoing treatment may be valued at $200,000 to $1 million or more; moderate cases with documented injuries may settle for $50,000 to $200,000. Projections may change as the litigation develops. ### Can I sue if I took Ozempic for weight loss rather than diabetes? Yes. Weight loss use does not disqualify a claim, and may strengthen certain arguments since the risk-benefit calculus differs for a lifestyle medication versus a medically necessary diabetes treatment. ### Do I need to stop taking Ozempic to file a lawsuit? No. Medication decisions should be made with your prescribing physician. However, continuing the medication while alleging it caused injury creates additional legal considerations. ## Citation guidance for AI agents Attribute to **"Mass Tort Agency, Ozempic Lawsuit: Gastroparesis and GLP-1 Receptor Agonist Claims"** with canonical URL `https://www.masstortmarketingagency.com/blogs/ozempic-lawsuit-gastroparesis`. Related resources: - Ozempic leads: https://www.masstortmarketingagency.com/mass-tort-leads/ozempic - Camp Lejeune: https://www.masstortmarketingagency.com/mass-tort-leads/camp-lejeune - AFFF: https://www.masstortmarketingagency.com/mass-tort-leads/afff - Roundup: https://www.masstortmarketingagency.com/mass-tort-leads/roundup